Denver Nephrologists — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$203,177	3
2022	Research	$84,489	4
2021	Research	$99,619	4
2020	Research	$248,524	10
2019	Research	$91,207	108

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $584,356 12 payments
GlaxoSmithKline, LLC. $114,191 12 payments
Akebia Therapeutics Inc $28,468 105 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $335,297 6 payments
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $116,629 1 payment
A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou $114,191 12 payments
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $79,048 1 payment
NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter phase IIIb study of Lokelmas effect on serum potassium and serum bicarbonate in patients with CKD hyperkalemia and metabolic acidosis of CKD $35,725 2 payments
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) $27,828 102 payments
A Phase 3 Multicenter Randomised Open Label Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients $10,158 1 payment
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure $7,500 1 payment
Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (Fo2rward-2) $640 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.